Compare Organon & Co. Common Stock (OGN) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Vertex Pharmaceuticals Incorporated — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Vertex Pharmaceuticals Incorporated trades at $507.99 (market cap $122.98B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 34× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| OGN | VRTX | |
|---|---|---|
Market Cap | $3.62B | $122.98B |
Volume | 2,892,999 | 1,155,743 |
Sector | Health | Health |
52-Week High | $13.81 | $557.96 |
52-Week Low | $5.70 | $407.90 |
Typical Hold Time | 0 Days | 120 Days |
Enterprise Value | $11.04B | $117.11B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Vertex Pharmaceuticals (VRTX) trades at $485.22, down 4.3% amid a bearish technical signal, though fundamentals remain strong with 2025 revenue of $12.0B and net income of $3.95B. The company maintains dominant cystic fibrosis market position and shows positive Phase II data for kidney disease drug inaxaplin. Analyst consensus is strongly bullish with 85.7% buy ratings and $573.50 price target, representing 18% upside potential from current levels.
Vertex presents a compelling growth story with robust profitability (35% net margin) and expanding pipeline, though recent earnings misses and competitive pressures warrant caution. The stock's current dip may offer entry opportunity for long-term investors, with key catalysts including regulatory decisions and pipeline advancements expected in early 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
